| (Values in U.S. Thousands) | Dec, 2019 | Dec, 2018 | Dec, 2017 | Dec, 2016 | Dec, 2015 |
| Sales | 2,330 | 2,360 | 3,090 | 2,390 | 2,390 |
| Sales Growth | -1.27% | -23.62% | +29.29% | unch | -17.01% |
| Net Income | 530 | -3,100 | -5,020 | -9,020 | -9,040 |
| Net Income Growth | +117.10% | +38.25% | +44.35% | +0.22% | -130.61% |
Tbg Diagnostics Ltd (TDLAF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
TBG Diagnostics Limited is a molecular diagnostics company. It engaged in the development, manufacture and marketing of molecular diagnostics kits, instruments and services. The company operates primarily in the US, Taiwan and China. TBG Diagnostics Limited, formerly known as Progen Pharmaceuticals Limited, is based in Darra, Australia.
Fiscal Year End Date: 12/31